Management of Atomoxetine‑Induced Fatigue

Onset and Early Course

• Fatigue usually appears early in the treatment course, especially when the dose is increased rapidly, and is often accompanied by initial somnolence and gastrointestinal symptoms. 1

Dosing Strategies to Reduce Fatigue

• Initiate therapy at low doses and titrate slowly to lessen early somnolence and fatigue. 1
• In pediatric patients, start at 0.5 mg/kg/day for at least 3 days before increasing to a target of approximately 1.2 mg/kg/day. 2
• In adult patients, begin with 40 mg/day and gradually increase to 80–100 mg/day over several weeks. 2

Monitoring Fatigue

• Evaluate fatigue severity at every visit during the first 6–12 weeks of therapy, the period required for atomoxetine to reach its full therapeutic effect. 2
• Apply standardized rating scales to differentiate medication‑related fatigue from residual ADHD symptoms. 3

Safety Monitoring Beyond Fatigue

• Screen for suicidal ideation during the initial weeks of treatment and after any dose change, in accordance with the FDA black‑box warning. 1
• Measure blood pressure and heart rate at baseline and throughout titration. 1
• Obtain a cardiovascular history before starting atomoxetine. 1
• Monitor growth parameters in children, recognizing that atomoxetine may cause a temporary growth delay that typically resolves after 2–3 years. 1

Indications for Switching to a Stimulant

• If fatigue persists despite dose adjustments after 6 weeks of therapeutic dosing, consider transitioning to a stimulant medication. 3
• Stimulants (e.g., methylphenidate, lisdexamfetamine) show larger effect sizes (≈ 70–80 % response rates) and produce clinical improvement within days rather than weeks. 3
• Long‑acting stimulant formulations are preferred for once‑daily dosing and better adherence. 3

Transition Protocol

• Atomoxetine can be discontinued abruptly; no taper or washout period is required before initiating a stimulant. 3
• Start methylphenidate OROS at 18 mg once daily or lisdexamfetamine at 20–30 mg once daily. 3
• Titrate the stimulant weekly based on clinical response and tolerability. 3

Patient Populations in Which Atomoxetine Remains Preferred

• Individuals with comorbid substance‑use disorders, because atomoxetine has no abuse potential. 2
• Patients with comorbid tic disorders or anxiety, who may experience greater benefit from atomoxetine than from stimulants. 2
• Patients who decline controlled substances or have failed prior stimulant trials should continue atomoxetine despite fatigue if other ADHD symptoms improve. 2

The clinical decision hinges on whether fatigue improves with appropriate dose titration and a 6–12‑week observation period; persistent fatigue warrants a switch to a stimulant for superior efficacy and rapid onset. 3